Research
Hormonal
Insulin resistance is a central mechanism in Metabolic Syndrome, driven by impaired insulin signaling pathways (PI3K/Akt) and exacerbated by factors like saturated fatty acids, oxidative stress, and chronic inflammation.
Metabolic Syndrome is largely driven by insulin resistance, where your body's cells don't respond well to insulin. This leads to high blood sugar, fat storage, and other issues. Managing this involves addressing the root causes of insulin resistance through diet, exercise, and weight management.
StrongSupportsVERY_HIGH confidence
MetS is also widely known as insulin resistance syndrome [10,11] due to the causative role insulin resistance plays in the syndrome [12,13]. ... Under insulin resistance, the phosphorylation signaling pathway becomes impaired, which leads to decreased GLUT4 expression, or dysfunction of translocation, resulting in impaired glucose transport, suppressed glycogen storage, and inhibited protein synthesis.
Why this rating
The paper is a comprehensive review detailing multiple molecular pathways confirming insulin resistance.
Source
Etiology of Metabolic Syndrome and Dietary Intervention
Hang Xu et al. · International Journal of Molecular Sciences · 2018
DOI 10.3390/ijms20010128
narrative_reviewCited 263×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Improving cardiorespiratory fitness (CRF) is a more effective strategy for reducing mortality risk and improving pancreatic beta-cell function in metabolic syndrome than weight-loss strategies focused solely on fat loss.Good
- Omega-3 fatty acid supplementation reduces obesity-associated inflammation but does not necessarily improve insulin sensitivity or reduce body weight.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →